recombinant proteins

Summary

Summary: Proteins prepared by recombinant DNA technology.

Top Publications

  1. doi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  3. ncbi Protein production by auto-induction in high density shaking cultures
    F William Studier
    Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Protein Expr Purif 41:207-34. 2005
  4. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  5. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  6. doi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
  7. ncbi Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein
    Nathan C Shaner
    Nat Biotechnol 22:1567-72. 2004
  8. doi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
  9. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
  10. ncbi Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009

Research Grants

  1. Molecular Biology Core Laboratory
    David Russell; Fiscal Year: 2009
  2. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2003
  3. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2002
  4. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2001
  5. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2000
  6. MECHANISM BASED DRUG SELECTION AND DESIGN--NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 1999
  7. ADMINISTRATIVE CORE
    Dennis L Kasper; Fiscal Year: 2011
  8. DCTD Biopharmaceutical Development - Type 1 Diabetes RAID projects
    LARRY ARTHUR; Fiscal Year: 2009
  9. DCTD Biopharmaceutical Development
    LARRY ARTHUR; Fiscal Year: 2009
  10. DCTD Biopharmaceutical Development
    David Heimbrook; Fiscal Year: 2012

Detail Information

Publications338 found, 100 shown here

  1. doi Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Dongliang Ge
    Institute for Genome Sciences and Policy, Center for Human Genome Variation, Duke University, Durham, North Carolina 27708, USA
    Nature 461:399-401. 2009
    ....
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  3. ncbi Protein production by auto-induction in high density shaking cultures
    F William Studier
    Biology Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    Protein Expr Purif 41:207-34. 2005
    ..Selenomethionine labeling was equally efficient in the commonly used methionine auxotroph B834(DE3) (found to be metE) or the prototroph BL21(DE3)...
  4. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  5. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  6. doi Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University, Durham, NC 27715, USA
    N Engl J Med 360:1827-38. 2009
    ..Telaprevir, a protease inhibitor specific to the HCV nonstructural 3/4A serine protease, rapidly reduced HCV RNA levels in early studies...
  7. ncbi Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein
    Nathan C Shaner
    Nat Biotechnol 22:1567-72. 2004
    ..Three monomers with distinguishable hues from yellow-orange to red-orange have higher quantum efficiencies...
  8. doi Telaprevir and peginterferon with or without ribavirin for chronic HCV infection
    Christophe Hezode
    Assistance Publique Hopitaux de Paris, Henri Mondor Hospital, University of Paris 12 and INSERM Unité 955, Creteil, France
    N Engl J Med 360:1839-50. 2009
    ..Telaprevir is a specific inhibitor of the HCV serine protease and could be of value in HCV treatment...
  9. ncbi Telaprevir for previously treated chronic HCV infection
    John G McHutchison
    Duke Clinical Research Institute and Duke University Medical Center, Durham, NC, USA
    N Engl J Med 362:1292-303. 2010
    ..Patients with genotype 1 hepatitis C virus (HCV) who do not have a sustained response to therapy with peginterferon alfa and ribavirin have a low likelihood of success with retreatment...
  10. ncbi Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
    John G McHutchison
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 361:580-93. 2009
    ..Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared...
  11. ncbi Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
    Andri Rauch
    University Clinic of Infectious Diseases, University Hospital Bern and University of Bern, Bern, Switzerland
    Gastroenterology 138:1338-45, 1345.e1-7. 2010
    ..We performed a genome-wide association study to screen for host genetic determinants of HCV persistence and response to therapy...
  12. pmc High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells
    Yves Durocher
    Animal Cell Technology and Downstream Processing Group, Biotechnology Research Institute, National Research Council Canada, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2, Canada
    Nucleic Acids Res 30:E9. 2002
    ..Using the pTT vector, >20 mg/l of purified His-tagged SEAP was recovered from a 3.5 l bioreactor. Intracellular proteins were also produced at levels as high as 50 mg/l, representing up to 20% of total cell proteins...
  13. ncbi Functional interaction of beta-catenin with the transcription factor LEF-1
    J Behrens
    Max Delbruck Centre for Molecular Medicine, Berlin, Germany
    Nature 382:638-42. 1996
    ..Thus beta-catenin regulates gene expression by direct interaction with transcription factors such as LEF-1, providing a molecular mechanism for the transmission of signals, from cell-adhesion components or wnt protein to the nucleus...
  14. ncbi HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
    Y Feng
    Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases NIAID, NIH, Bethesda, MD 20892, USA
    Science 272:872-7. 1996
    ..Fusin messenger RNA levels correlated with HIV-1 permissiveness in diverse human cell types. Fusin acted preferentially for T cell line-tropic isolates, in comparison to its activity with macrophagetropic HIV-1 isolates...
  15. ncbi Generation of induced pluripotent stem cells using recombinant proteins
    Hongyan Zhou
    Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cell Stem Cell 4:381-4. 2009
  16. ncbi Effects of the obese gene product on body weight regulation in ob/ob mice
    M A Pelleymounter
    Department of Neurobiology, Amgen, Inc, Thousand Oaks, CA 91320, USA
    Science 269:540-3. 1995
    ..These data suggest that the OB protein regulates body weight and fat deposition through effects on metabolism and appetite...
  17. ncbi Correction of anemia with epoetin alfa in chronic kidney disease
    Ajay K Singh
    Renal Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 355:2085-98. 2006
    ..Recombinant human erythropoietin (epoetin alfa) is indicated for the correction of anemia associated with this condition. However, the optimal level of hemoglobin correction is not defined...
  18. ncbi Recombinant protein expression in Escherichia coli
    F Baneyx
    Department of Chemical Engineering University of Washington Box 351750, Seattle, WA 98195, USA
    Curr Opin Biotechnol 10:411-21. 1999
    ..coli, together with serendipitous discoveries and the availability of improved genetic tools are making this bacterium more valuable than ever for the expression of complex eukaryotic proteins...
  19. ncbi Nuclear export of microRNA precursors
    Elsebet Lund
    Department of Biomolecular Chemistry, University of Wisconsin Medical School, Madison, WI 53706, USA
    Science 303:95-8. 2004
    ..Thus, Exp5 is key to miRNA biogenesis and may help coordinate nuclear and cytoplasmic processing steps...
  20. ncbi Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008
    R Phillip Dellinger
    Cooper University Hospital, Camden, NJ, USA
    Crit Care Med 36:296-327. 2008
    ..To provide an update to the original Surviving Sepsis Campaign clinical management guidelines, "Surviving Sepsis Campaign Guidelines for Management of Severe Sepsis and Septic Shock," published in 2004...
  21. doi Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    ..To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C...
  22. ncbi Binding of hepatitis C virus to CD81
    P Pileri
    IRIS, Chiron, Siena 53100, Italy
    Science 282:938-41. 1998
    ..Binding of E2 was mapped to the major extracellular loop of CD81. Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro...
  23. pmc Interferon signaling and treatment outcome in chronic hepatitis C
    Magdalena Sarasin-Filipowicz
    Department of Biomedicine, University of Basel, CH 4031 Basel, Switzerland
    Proc Natl Acad Sci U S A 105:7034-9. 2008
    ....
  24. ncbi Identification of a major co-receptor for primary isolates of HIV-1
    H Deng
    Skirball Institute for Biomolecular Medicine, New York University Medical Center, 10016, USA
    Nature 381:661-6. 1996
    ..The principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR-5, a receptor for the beta-chemokines RANTES, MIP-1alpha and MIP-1beta...
  25. ncbi Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
    Christoph Sarrazin
    Klinik fur Innere Medizin II, Universitat des Saarlandes, Homburg Saar, Germany
    Gastroenterology 132:1767-77. 2007
    ..4A protease inhibitor, has shown strong antiviral activity in phase 1 clinical studies. Because of high levels of HCV replication and the low fidelity of HCV polymerase, selection of resistant isolates during therapy may occur...
  26. pmc Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin
    Jeanette J McCarthy
    Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27708, USA
    Gastroenterology 138:2307-14. 2010
    ..We investigated the association between the polymorphism rs12979860 and treatment response in a diverse cohort of chronic HCV patients...
  27. ncbi Normalization of hemoglobin level in patients with chronic kidney disease and anemia
    Tilman B Drueke
    Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
    N Engl J Med 355:2071-84. 2006
    ..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established...
  28. doi Genome sequence of the recombinant protein production host Pichia pastoris
    Kristof De Schutter
    Unit for Molecular Glycobiology, Department for Molecular Biomedical Research, VIB, Ghent Zwijnaarde, Belgium
    Nat Biotechnol 27:561-6. 2009
    ..pastoris. To facilitate progress in these areas, we present the 9.43 Mbp genomic sequence of the GS115 strain of P. pastoris. We also provide manually curated annotation for its 5,313 protein-coding genes...
  29. doi Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients
    Ming Lung Yu
    Department of Internal Medicine, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan
    Hepatology 53:7-13. 2011
    ..99-1.00, P = 0.04). Nevertheless, the achievement of RVR was the single predictor of SVR with an OR of 19.37 (95% CI = 8.89-42.23, P < 0.001), whereas the rs8099917 genotypes played no role in achieving SVR with or without RVR...
  30. pmc Genome-scale metabolic reconstruction and in silico analysis of methylotrophic yeast Pichia pastoris for strain improvement
    Bevan Ks Chung
    NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, 28 Medical Drive, 05 01, 117456, Singapore
    Microb Cell Fact 9:50. 2010
    ..pastoris can be employed together with high throughput experimental data analysis, for better understanding of the methylotrophic yeast's metabolism...
  31. pmc High-throughput production of human proteins for crystallization: the SGC experience
    Pavel Savitsky
    Structural Genomics Consortium, University of Oxford, Old Road Campus Research Building, Oxford, UK
    J Struct Biol 172:3-13. 2010
    ..These can be used to formulate guidelines for initial approaches to expression of new eukaryotic proteins...
  32. doi Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    Paul Y Kwo
    Department of Medicine, Division of Gastroenterology Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202 5121, USA
    Lancet 376:705-16. 2010
    ..We tested the efficacy of boceprevir, an NS3 hepatitis C virus oral protease inhibitor, when added to peginterferon alfa-2b and ribavirin...
  33. ncbi Heterologous protein production using the Pichia pastoris expression system
    Sue Macauley-Patrick
    Strathclyde Fermentation Centre, Department of Bioscience, University of Strathclyde, 204 George Street, Glasgow G1 1XW, UK
    Yeast 22:249-70. 2005
    ..The problems associated with post-translational modifications performed on recombinant proteins by P...
  34. ncbi Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
    Manuel Romero-Gomez
    Hepatology Unit, Hospital Universitario de Valme, Sevilla, Spain
    Gastroenterology 128:636-41. 2005
    ..We evaluated the effect of insulin resistance and viral factors on sustained virological response in patients with chronic hepatitis C treated with peginterferon plus ribavirin...
  35. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  36. ncbi Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution
    R B Sutton
    The Howard Hughes Medical Institute, Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520, USA
    Nature 395:347-53. 1998
    ..These characteristics may be important for membrane fusion and for the binding of regulatory factors affecting neurotransmission...
  37. doi 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    M S Aapro
    Multidisciplinary Oncology Institute, Clinique de Genolier, 1, route du Muids, 1272 Genolier, Switzerland
    Eur J Cancer 47:8-32. 2011
    ..Evidence from multiple low level studies derived from audit data and clinical practice suggests that some patients receive suboptimal daily G-CSFs; the use of pegfilgrastim may avoid this problem...
  38. doi Recombinant protein production in a variety of Nicotiana hosts: a comparative analysis
    Andrew J Conley
    Department of Biology, University of Western Ontario, London, ON, Canada
    Plant Biotechnol J 9:434-44. 2011
    ..biopharmaceuticals and industrial enzymes, tobacco has the most established history for the production of recombinant proteins. To further improve the heterologous protein yield of tobacco platforms, transient and stable expression of ..
  39. pmc Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E.coli
    Van Dat Nguyen
    Department of Biochemistry, Linnanmaa campus, University of Oulu, 90570 Oulu, Finland
    Microb Cell Fact 10:1. 2011
    ..We have recently shown that it is possible to produce large amounts of prokaryotic disulfide bond containing proteins in the cytoplasm of wild-type bacteria such as E. coli by the introduction of catalysts for both of these processes...
  40. pmc Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
    Jing Xu
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA
    Diabetes 58:250-9. 2009
    ..The aims of the current study are to evaluate the role of FGF21 in energy metabolism and to provide mechanistic insights into its glucose and lipid-lowering effects in a high-fat diet-induced obesity (DIO) model...
  41. doi Engineering of protein secretion in yeast: strategies and impact on protein production
    Alimjan Idiris
    R and D Group, ASPEX Division, Research Center, Asahi Glass Co, Ltd, 1150 Hazawa cho, Kanagawa ku, Yokohama, 221 8755, Japan
    Appl Microbiol Biotechnol 86:403-17. 2010
    ..This mini-review focuses on recent strategies and their advantages for systematic engineering of yeast strains for effective protein secretion...
  42. ncbi Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
    Antonio Ascione
    Department of Gastroenterology, Liver Unit, Cardarelli Hospital, Napoli, Italy
    Gastroenterology 138:116-22. 2010
    ..This study compared the efficacy and safety of peginterferon alfa-2a and peginterferon alfa-2b, each in combination with ribavirin...
  43. doi Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response
    M Brines
    Warren Pharmaceuticals, Ossining, NY 10562, USA
    J Intern Med 264:405-32. 2008
    ....
  44. pmc Functional amyloid formation within mammalian tissue
    Douglas M Fowler
    Department of Chemistry, The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, California, USA
    PLoS Biol 4:e6. 2006
    ....
  45. pmc Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870
    Vega Masignani
    IRIS, Chiron Srl, Via Fiorentina 1, 53100 Siena, Italy
    J Exp Med 197:789-99. 2003
    ..The novel antigen is a top candidate for the development of a new vaccine against meningococcus...
  46. ncbi A companion protease inhibitor for the protection of cytosol-targeted recombinant proteins in plants
    Charles Goulet
    CRH INAF, Pavillon des Services INAF, Universite Laval, Quebec, QC, Canada
    Plant Biotechnol J 8:142-54. 2010
    ..potential of tomato cathepsin D inhibitor (SlCDI) as an in-built stabilizing agent for the protection of recombinant proteins in transgenic plant leaf crude extracts (Plant Biotechnol J.4, 359-368)...
  47. doi Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria
    Jerry M Wells
    Host Microbe Interactomics, University of Wageningen, Animal Sciences Department, P O Box 338, 6700 AH, Wageningen, The Netherlands
    Nat Rev Microbiol 6:349-62. 2008
    ....
  48. ncbi Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
    A Furlan
    Cerebrovascular Center, Department of Neurology, Cleveland Clinic Foundation, Ohio 44195, USA
    JAMA 282:2003-11. 1999
    ..Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed...
  49. ncbi Cloning of a new cytokine that induces IFN-gamma production by T cells
    H Okamura
    Department of Bacteriology, Hyogo College of Medicine, Nishinomiya, Japan
    Nature 378:88-91. 1995
    ..IGIF may be involved in the development of Th1 cells and also in mechanisms of tissue injury in inflammatory reactions...
  50. ncbi 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis
    Igor Mierau
    NIZO Food Research, P O Box 20, 6710, Ede, The Netherlands
    Appl Microbiol Biotechnol 68:705-17. 2005
    ..Finally, an overview is given of growth and induction conditions for lab-scale and industrial-scale applications...
  51. ncbi Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities
    Christopher M Jenkins
    Division of Bioorganic Chemistry and Molecular Pharmacology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 279:48968-75. 2004
    ....
  52. pmc Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
    Leah D Fletcher
    Wyeth Vaccines Research, Pearl River, New York 10965, USA
    Infect Immun 72:2088-100. 2004
    ..The rLP2086 family of antigens are candidates worthy of further vaccine development...
  53. doi Hepatitis C pharmacogenetics: state of the art in 2010
    Nezam H Afdhal
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Hepatology 53:336-45. 2011
    ....
  54. pmc Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response
    Sebastián Bernales
    Howard Hughes Medical Institute, University of California San Francisco, San Francisco, California, United States of America
    PLoS Biol 4:e423. 2006
    ..Selective ER sequestration may help cells to maintain a new steady-state level of ER abundance even in the face of continuously accumulating unfolded proteins...
  55. ncbi Side effects of therapy of hepatitis C and their management
    Michael W Fried
    Division of Digestive Diseases, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Hepatology 36:S237-44. 2002
    ..Strategies to maximize adherence are being developed and, in the future, may include early identification of and therapy for depression and the selective use of hematopoietic growth factors to ameliorate hematologic abnormalities...
  56. doi Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease
    Ari Zimran
    Gaucher Clinic, Shaare Zedek Medical Center, Hadassah Medical School, Hebrew University, Jerusalem, Israel
    Blood 118:5767-73. 2011
    ..4, -32.8) in the 60-unit dose group (both P < .0001); and in all secondary efficacy end point measures, except platelet counts at the lower dose. These results support safety and efficacy of taliglucerase alfa for Gaucher disease...
  57. ncbi Structure and function of fatty acid amide hydrolase
    Michele K McKinney
    Departments of Cell Biology and Chemistry, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Annu Rev Biochem 74:411-32. 2005
    ..These studies, as well as their biological and therapeutic implications, are the subject of this review...
  58. ncbi Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Thoracic Head and Neck Medicine Clinic, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
    J Clin Oncol 28:2839-46. 2010
    ..To the best of our knowledge, this is the first in-human clinical trial to assess the safety, tolerability, pharmacokinetics, and antitumor activity of multiple intravenous doses of rhApo2L/TRAIL in patients with advanced cancer...
  59. pmc Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120
    Ralph Pantophlet
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:642-58. 2003
    ..These reengineered gp120s are prospective immunogens that may prove capable of eliciting broadly neutralizing antibodies...
  60. pmc Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients
    Tatsuo Miyamura
    Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan
    PLoS ONE 6:e28617. 2011
    ....
  61. pmc Lytic activity of the virion-associated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS-phiIPLA88
    Lorena Rodriguez
    Instituto de Productos Lacteos de Asturias IPLA CSIC, Apdo, Asturias, Spain
    BMC Microbiol 11:138. 2011
    ..In this context, bacteriophage lytic enzymes such as endolysins and structural peptidoglycan (PG) hydrolases have received considerable attention as possible antimicrobials against gram-positive bacteria...
  62. ncbi Green fluorescent protein as a marker for gene expression
    M Chalfie
    Department of Biological Sciences, Columbia University, New York, NY 10027
    Science 263:802-5. 1994
    ..Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms...
  63. ncbi The production of recombinant pharmaceutical proteins in plants
    Julian K C Ma
    Department of Infectious Diseases, St George s Hospital Medical School, Cranmer Terrace, London SW17 0RE, UK
    Nat Rev Genet 4:794-805. 2003
    ..This could one day become reality as we learn to harness the power of plants for the production of recombinant proteins on an agricultural scale...
  64. ncbi Peginterferon alfa-2a in patients with chronic hepatitis C
    S Zeuzem
    Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    N Engl J Med 343:1666-72. 2000
    ..We compared the clinical effects of a regimen of peginterferon alfa-2a with those of a regimen of interferon alfa-2a in the initial treatment of patients with chronic hepatitis C...
  65. pmc Full-length extracellular region of the var2CSA variant of PfEMP1 is required for specific, high-affinity binding to CSA
    Anand Srivastava
    Institut Pasteur, Unité de Biologie des Interactions Hôte Parasite, Centre National de la Recherche Scientifique Unité de Recherche Associée 2581, 25 rue du Docteur Roux, F 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 107:4884-9. 2010
    ..These results have important consequences for the development of an effective vaccine and therapeutic inhibitors...
  66. pmc In planta protein sialylation through overexpression of the respective mammalian pathway
    Alexandra Castilho
    Department of Applied Genetics and Cell Biology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
    J Biol Chem 285:15923-30. 2010
    ..Besides the biotechnological impact of the achievement, this work may serve as a general model for the manipulation of complex traits into plants...
  67. pmc Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies
    Pongsak Khunrae
    Department of Biochemistry, University of Cambridge, Cambridge, UK
    J Mol Biol 397:826-34. 2010
    ..The specificity of the binding and anti-adhesion potency of induced IgG, together with high-yield production, encourages the use of full-length PfEMP1 in vaccine development strategies...
  68. ncbi Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
    M L Moss
    Department of Molecular Biochemistry, Glaxo Wellcome Research and Development Inc, Research Triangle Park, North Carolina 27709, USA
    Nature 385:733-6. 1997
    ..The rTACE provides a readily available source of enzyme to help in the search for new anti-inflammatory agents that target the final processing stage of TNF-alpha production...
  69. doi Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
    Han Qing Jiang
    Pfizer Vaccine Research, 401N Middletown Rd, Pearl River, NY 10965, USA
    Vaccine 28:6086-93. 2010
    ..Importantly, epidemiologically prevalent fHBP variants from both subfamilies were killed...
  70. ncbi Expression of heterologous proteins in Pichia pastoris: a useful experimental tool in protein engineering and production
    Rachel Daly
    ARC Special Research Centre for Green Chemistry, Monash University, Building 23, Wellington Road, Clayton, Victoria 3800, Australia
    J Mol Recognit 18:119-38. 2005
    The use of the methylotrophic yeast, Pichia pastoris, as a cellular host for the expression of recombinant proteins has become increasing popular in recent times. P...
  71. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  72. pmc Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants
    Paul A Sieving
    National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 103:3896-901. 2006
    ..The approach to delivering therapeutic proteins to degenerating retinas using encapsulated cell implants may have application beyond disease caused by genetic mutations...
  73. pmc Inclusion bodies: a new concept
    Elena García-Fruitós
    CIBER en Bioingeniería, Biomateriales y Nanomedicina, Bellaterra, 08193 Barcelona, Spain
    Microb Cell Fact 9:80. 2010
    ..Therefore, the development of new purification protocols aimed to preserve those properties is becoming a pushing demand...
  74. ncbi Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes
    Ling Fu
    Genentech Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Endocrinology 145:2594-603. 2004
    ..Thus, FGF19 is able to increase metabolic rate concurrently with an increase in fatty acid oxidation...
  75. ncbi Biochemical characterization and ligand binding properties of neuroglobin, a novel member of the globin family
    S DeWilde
    Department of Biochemistry, University of Antwerp, B 2610 Antwerp, Belgium
    J Biol Chem 276:38949-55. 2001
    ..The biochemical and kinetic characteristics are discussed in view of the possible functions of neuroglobin in the vertebrate brain...
  76. ncbi Crystal structure of a mammalian voltage-dependent Shaker family K+ channel
    Stephen B Long
    Howard Hughes Medical Institute, Laboratory of Molecular Neurobiology and Biophysics, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 309:897-903. 2005
    ..Electrostatic properties of the side portals and positions of the T1 domain and beta subunit are consistent with electrophysiological studies of inactivation gating and with the possibility of K+ channel regulation by the beta subunit...
  77. ncbi Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  78. pmc Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state
    Hillel Haim
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA, USA
    PLoS Pathog 5:e1000360. 2009
    ..This novel strategy for inhibition may be generally applicable to high-potential-energy viral entry machines that are normally activated by receptor binding...
  79. pmc Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St Louis, MO 63110, USA
    N Engl J Med 359:2429-41. 2008
    ..Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain...
  80. pmc Generating a prion with bacterially expressed recombinant prion protein
    Fei Wang
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, OH 43210, USA
    Science 327:1132-5. 2010
    ..Thus, as postulated by the prion hypothesis, the infectivity in mammalian prion disease results from an altered conformation of PrP...
  81. pmc Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
    Q J Sattentau
    Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London, United Kingdom
    J Exp Med 174:407-15. 1991
    ..We propose that these events occurring after CD4 binding are integral components of the membrane fusion reaction between HIV or HIV-infected cells and CD4+ cells...
  82. pmc The Anopheles gambiae odorant binding protein 1 (AgamOBP1) mediates indole recognition in the antennae of female mosquitoes
    Harald Biessmann
    Developmental Biology Center, Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, United States of America
    PLoS ONE 5:e9471. 2010
    ..gambiae OBP-ligand pairing combination, demonstrates the significance of OBPs in odor recognition, and can be expanded to the identification of other ligands for OBPs of Anopheles and other medically important insects...
  83. ncbi Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein
    Ryuichiro Atarashi
    Laboratory of Persistent Viral Diseases, National Institutes of Health, 903 S 4th Street, Hamilton, Montana 59840, USA
    Nat Methods 4:645-50. 2007
    ..This method should facilitate the development of rapid, ultrasensitive prion assays and diagnostic tests, in addition to aiding fundamental studies of structure and mechanism of PrPSc formation...
  84. ncbi The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
    Alexei Kharitonenkov
    Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Endocrinology 148:774-81. 2007
    ..These data support the development of FGF-21 for the treatment of diabetes and other metabolic diseases...
  85. pmc Characterization of an Arabidopsis enzyme family that conjugates amino acids to indole-3-acetic acid
    Paul E Staswick
    Department of Agronomy and Horticulture, University of Nebraska, Lincoln, Nebraska 68583, USA
    Plant Cell 17:616-27. 2005
    ..This evidence establishes that several GH3 genes encode IAA-amido synthetases, which help to maintain auxin homeostasis by conjugating excess IAA to amino acids...
  86. pmc Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence
    Emma Langley
    Wellcome Institute Cancer Research UK and Department of Pathology, University of Cambridge, Tennis Court Road, CB2 1QR, UK
    EMBO J 21:2383-96. 2002
    ..Taken together, our data establish the SIRT1 deacetylase as a novel negative regulator of p53 function capable of modulating cellular senescence...
  87. doi Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
    Christoph Sarrazin
    Medizinische Klinik 1, J W Goethe University Hospital, Frankfurt am Main, Germany
    J Hepatol 54:415-21. 2011
    ..The importance of three IL28B single nucleotide polymorphisms (rs8099917, rs12980275 and rs12979860) for HCV genotype 2/3-infected patients is unknown...
  88. ncbi The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation
    Hulda Sigridur Hreggvidsdottir
    Department of Medicine, Rheumatology Research Unit, Karolinska Hospital, Karolinska Institutet, S 171 76 Stockholm, Sweden
    J Leukoc Biol 86:655-62. 2009
    ..HMGB1 thus acts broadly with many but not all immunostimulatory molecules to amplify their activity in a synergistic manner...
  89. ncbi Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases
    Monica Bucciantini
    Dipartimento di Scienze Biochimiche, Viale Morgagni 50, Universita degli Studi di Firenze, 50134 Firenze, Italy
    Nature 416:507-11. 2002
    ..This finding provides added evidence that avoidance of protein aggregation is crucial for the preservation of biological function and suggests common features in the origins of this family of protein deposition diseases...
  90. pmc Low micromolar zinc accelerates the fibrillization of human tau via bridging of Cys-291 and Cys-322
    Zhong Ying Mo
    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
    J Biol Chem 284:34648-57. 2009
    ....
  91. ncbi Single domain camel antibodies: current status
    S Muyldermans
    Vrije Universiteit Brussel, Vlaams Interuniversitair Instituut voor Biotechnologie, Sint Genesius Rode, Belgium
    J Biotechnol 74:277-302. 2001
    ..They are expected to open perspectives as enzyme inhibitors and intrabodies, as modular building units for multivalent or multifunctional constructs, or as immuno-adsorbents and detection units in biosensors...
  92. pmc Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates
    Rolando Pajon
    Center for Immunobiology and Vaccine Development, Children s Hospital Oakland Research Institute, 5700 Martin Luther King Jr Way, Oakland, CA 94609, USA
    Vaccine 28:2122-9. 2010
    ..The results confirmed the modular architecture of fHbp and underscored its importance for the design of broadly protective group B vaccines in different regions...
  93. ncbi Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Suzanne Hermeling
    Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences UIPS, Utrecht, The Netherlands
    Pharm Res 20:1903-7. 2003
    ..The aim of this study was to detect the mechanism by which the new formulation may induce these antibodies...
  94. ncbi Bone morphogenetic protein-1: the type I procollagen C-proteinase
    E Kessler
    Maurice and Gabriela Goldschleger Eye Research Institute, Tel Aviv University Sackler Faculty of Medicine, Sheba Medical Center, Tel Hashomer, Israel
    Science 271:360-2. 1996
    ..Here it is shown that BMP-1 and PCP are identical. This demonstration of enzymatic activity for a BMP-1/TLD-like protein links an enzyme involved in matrix deposition to genes involved in pattern formation...
  95. doi High efficacy of anti DBL4ɛ-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant women
    Pamela A Magistrado
    Centre for Medical Parasitology, Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
    Vaccine 29:437-43. 2011
    ..In this study, the binding inhibitory efficacy of IgG elicited by two different DBL4ɛ recombinant proteins was tested on a panel of fresh clinical isolates from pregnant women living in Benin and Tanzania...
  96. pmc Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases
    M B Calalb
    Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
    Mol Cell Biol 15:954-63. 1995
    ..Our results indicate that phosphorylation of FAK by Src (or other Src family kinases) is an important step in the formation of an active signaling complex...
  97. ncbi Transgenic chickens as bioreactors for protein-based drugs
    Simon G Lillico
    Roslin Institute, Roslin, Midlothian EH25 9PS, UK
    Drug Discov Today 10:191-6. 2005
    ....
  98. pmc Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation
    Hai Li Zhu
    State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China
    J Biol Chem 285:3592-9. 2010
    ....
  99. ncbi An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9
    H Zou
    Howard Hughes Medical Institute and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA
    J Biol Chem 274:11549-56. 1999
    ..The stoichiometric ratio of procaspase-9 to APAF-1 is approximately 1 to 1 in the complex. Once activated, caspase-9 disassociates from the complex and becomes available to cleave and activate downstream caspases such as caspase-3...
  100. pmc Cloning, expression and characterization of gE protein of duck plague virus
    Hua Chang
    Avian Diseases Research Center, College of Veterinary Medicine of Sichuan Agricultural University, Yaan, Sichuan, China
    Virol J 7:120. 2010
    ..The gE protein of duck plague virus is the important membrane glycoprotein, its protein characterization has not been reported. In this study, we expressed and presented the characterization of the DPV gE product...
  101. ncbi Structure and ligand of a histone acetyltransferase bromodomain
    C Dhalluin
    Structural Biology Program, Department of Physiology and Biophysics, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Nature 399:491-6. 1999
    ..Thus, the bromodomain is functionally linked to the HAT activity of co-activators in the regulation of gene transcription...

Research Grants82

  1. Molecular Biology Core Laboratory
    David Russell; Fiscal Year: 2009
    ..facility are used extensively to assess protein purification, immunoprecipitation from cells, expression of recombinant proteins, and immunoblotting from cultured cells, tissues, and recombinant hosts...
  2. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2003
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  3. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2002
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  4. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2001
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  5. MECHANISM-BASED DRUG SELECTION AND DESIGN: NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 2000
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  6. MECHANISM BASED DRUG SELECTION AND DESIGN--NUCLEOTIDE SA
    Buddy Ullman; Fiscal Year: 1999
    ..ii) Recombinant proteins. E. coli that overexpresses T...
  7. ADMINISTRATIVE CORE
    Dennis L Kasper; Fiscal Year: 2011
    ..The NERCE Biomolecule Production Core has assisted investigators with the production of over 100 different recombinant proteins and carbohydrate preparations;this core has conducted nearly 300 fermentations, resulting in 44 kg of ..
  8. DCTD Biopharmaceutical Development - Type 1 Diabetes RAID projects
    LARRY ARTHUR; Fiscal Year: 2009
    ..uses leading-edge technologies for development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other ..
  9. DCTD Biopharmaceutical Development
    LARRY ARTHUR; Fiscal Year: 2009
    ..uses leading-edge technologies for development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other ..
  10. DCTD Biopharmaceutical Development
    David Heimbrook; Fiscal Year: 2012
    ..uses leading-edge technologies for development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other ..
  11. DCTD Biopharmaceutical Development
    LARRY ARTHUR; Fiscal Year: 2010
    ..uses leading-edge technologies for development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other ..
  12. DCTD Biopharmaceutical Development
    David Heimbrook; Fiscal Year: 2011
    ..uses leading-edge technologies for development of monoclonal antibodies, cytokines, immunotoxins and other recombinant proteins, peptide and DNA vaccines, virus vaccines and targeted cytolytic viruses, gene therapy products, and other ..
  13. A novel transgenic silkworm system for recombinant glycoprotein production
    Donald Jarvis; Fiscal Year: 2009
    ..protein production and secretion organ, can be genetically engineered to efficiently produce and secrete recombinant proteins. But, transgenic silkworms have been neither developed nor used for recombinant glycoprotein production...
  14. A novel transgenic silkworm system for recombinant glycoprotein production
    Donald Jarvis; Fiscal Year: 2007
    ..protein production and secretion organ, can be genetically engineered to efficiently produce and secrete recombinant proteins. But, transgenic silkworms have been neither developed nor used for recombinant glycoprotein production...
  15. A novel transgenic silkworm system for recombinant glycoprotein production
    Donald L Jarvis; Fiscal Year: 2010
    ..protein production and secretion organ, can be genetically engineered to efficiently produce and secrete recombinant proteins. But, transgenic silkworms have been neither developed nor used for recombinant glycoprotein production...
  16. Development of an Algae-based Membrane Protein Expression System
    ALEXANDER ARAVANIS; Fiscal Year: 2009
    ..These chimeric recombinant proteins accumulate to relatively high levels in thylakoids, demonstrating that these membranes are capable of ..
  17. Geographically robust rapid assay for T. cruzi infection
    SYAMAL X RAYCHAUDHURI; Fiscal Year: 2010
    ..In this application, we have described a number of multi-antigenic fusion recombinant proteins including proprietary ITC6 and ITC8.2. The ITC8...
  18. Geographically robust rapid assay for T. cruzi infection
    SYAMAL RAYCHAUDHURI; Fiscal Year: 2009
    ..In this application, we have described a number of multi-antigenic fusion recombinant proteins including proprietary ITC6 and ITC8.2. The ITC8...
  19. Targeted delivery of osteoinductive molecules to biologic HA in bone grafts
    Jennifer L Bain; Fiscal Year: 2012
    ..comprised of a highly negative heptaglutamate sequence (E7) that can be added to synthetic peptides and recombinant proteins to achieve an increased concentration, as well as greater retention, of these agents on HA surfaces, thus ..
  20. A SARS-CoV Spike Protein Vaccine
    B Sim; Fiscal Year: 2005
    ..indicates that altering codon usage based on our proprietary information leads to enhanced expression of recombinant proteins and in vivo expression of proteins by DNA vaccines...
  21. A SARS-CoV Spike Protein Vaccine
    B Sim; Fiscal Year: 2004
    ..indicates that altering codon usage based on our proprietary information leads to enhanced expression of recombinant proteins and in vivo expression of proteins by DNA vaccines...
  22. Oral Delivery of protein antigens and their stability by Alginate Microspheres
    RAVI PALANIAPPAN; Fiscal Year: 2007
    ..prevent interaction with the alginate matrix, protect against enteric degradation and extend the release of recombinant proteins. Our preliminary study shows that Alginate microspheres (PACEA) release their entrapped proteins over 90 ..
  23. GENE THERAPY FOR HEMOPHILIA
    Mark Kay; Fiscal Year: 2005
    ..Work with recombinant proteins has established that hemophilia, caused by mutations in genes encoding Factors VIII or IX in the intrinsic ..
  24. Development of a Cytokine Release Assay as a Diagnostic Test for Lyme Disease
    PAUL MICHAEL ARNABOLDI; Fiscal Year: 2012
    ..However, serological assays using native or recombinant proteins from B...
  25. MOLECULAR BASIS AND ENZYMOLOGY OF MICROBIAL BIOSYNTHESIS
    F Tabita; Fiscal Year: 1992
    ..Both recombinant proteins in Escherichia coli, and many of the recombinant proteins purified to homogeneity...
  26. MOLECULAR BASIS AND ENZYMOLOGY OF MICROBIAL BIOSYNTHESIS
    F Tabita; Fiscal Year: 1993
    ..Both recombinant proteins in Escherichia coli, and many of the recombinant proteins purified to homogeneity...
  27. The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin
    Stuart Kahn; Fiscal Year: 2009
    ..Alternative treatments include oral drugs that are more toxic, injectable MTX, or injectable recombinant proteins (biologics) that are very expensive...
  28. Recombinant antigen assays for Lassa and other arenaviru
    Robert Garry; Fiscal Year: 2005
    ..GP1 and GP2, and the nucleoprotein (NP) will be expressed in bacteria or eukaryotic cell lines, and the recombinant proteins will be used to immunize mice and rhesus macaques...
  29. Vaccination Against Ixodes scapularis Tick Bites
    Michel Ledizet; Fiscal Year: 2002
    ..Phase I experiments evaluated Salp13 and Salp25D, two recombinant proteins expressed from I. scapularis salivary gland cDNAs, as candidate vaccines...
  30. Vaccination Against Ixodes scapularis Tick Bites
    Michel Ledizet; Fiscal Year: 2003
    ..Phase I experiments evaluated Salp13 and Salp25D, two recombinant proteins expressed from I. scapularis salivary gland cDNAs, as candidate vaccines...
  31. BIOLOGIC AND IMMUNOLOGIC ASPECTS OF TRANSFUSION MEDICINE
    Sherrill Slichter; Fiscal Year: 2009
    ..of T-cell epitopes in FVIII may lead to non-immunogenic FVIII replacement therapy while new peptides or recombinant proteins may be useful in tolerance induction for patients with existing antibodies...
  32. BIOLOGIC AND IMMUNOLOGIC ASPECTS OF TRANSFUSION MEDICINE
    Sherrill Slichter; Fiscal Year: 2006
    ..of T-cell epitopes in FVIII may lead to non-immunogenic FVIII replacement therapy while new peptides or recombinant proteins may be useful in tolerance induction for patients with existing antibodies...
  33. BIOLOGIC AND IMMUNOLOGIC ASPECTS OF TRANSFUSION MEDICINE
    Sherrill Slichter; Fiscal Year: 2005
    ..of T-cell epitopes in FVIII may lead to non-immunogenic FVIII replacement therapy while new peptides or recombinant proteins may be useful in tolerance induction for patients with existing antibodies...
  34. BIOLOGIC AND IMMUNOLOGIC ASPECTS OF TRANSFUSION MEDICINE
    Sherrill Slichter; Fiscal Year: 2007
    ..of T-cell epitopes in FVIII may lead to non-immunogenic FVIII replacement therapy while new peptides or recombinant proteins may be useful in tolerance induction for patients with existing antibodies...
  35. REGULATION OF PHOSPHOLIPASE C
    T Harden; Fiscal Year: 2000
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  36. REGULATION OF PHOSPHOLIPASE C
    T Harden; Fiscal Year: 1993
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  37. REGULATION OF PHOSPHOLIPASE C
    T Harden; Fiscal Year: 2001
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  38. REGULATION OF PHOSPHOLIPASE C
    T Harden; Fiscal Year: 2002
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  39. REGULATION OF PHOSPHOLIPASE C
    T Harden; Fiscal Year: 1999
    ..and the specificity of their activation by G(alpha(11) and G(alpha)(g) will be determined with native and recombinant proteins. The possibility that one or more of the PLC isoenzymes is activated by pertussis toxin- sensitive G-..
  40. Retasking an FDA-approved Drug for use in Peripheral Nerve Regeneration
    Melitta Schachner; Fiscal Year: 2012
    ..Many enhancers, such as recombinant proteins, cells and cellular components, have proven effective in small animal models and have even been translated ..
  41. Novel Simulated Moving Bed Chromatography Device to Purify Recombinant Proteins
    ROBERT MIERENDORF; Fiscal Year: 2007
    ..Initiative has been successful in developing high-throughput methods for structural determination of recombinant proteins, focusing on the so-called "low-hanging fruit", i.e...
  42. A Heterologous Expression System for Apicomplexa Genes
    JOSE FERNANDEZ ROBLEDO; Fiscal Year: 2009
    ..parasites available, it becomes evident the need for heterologous expression systems that can generate recombinant proteins, a step required for characterization of protein function, structural studies, production of antigen, ..
  43. REGULATION OF TRYPANOSOME DNA REPLICATION
    Dan S Ray; Fiscal Year: 2010
    ..The availability of a mitochondrial DNA primase will form the basis of an in vitro system using recombinant proteins and plasmid templates containing minicircle or maxicircle replication origins...
  44. Bioactive Peptide Coatings for Synthetic Bone Grafts in Dental Applications
    HANNE GRON; Fiscal Year: 2007
    ..will significantly improve their ability to retain exogenously delivered osteogenic factors such as recombinant proteins and progenitor cells...
  45. Preclinical development of recombinant antigen diagnostics for Lassa fever
    Robert Garry; Fiscal Year: 2009
    ..team has successfully produced prototype LASV enzyme-linked immunosorbent assays (ELISA) that are based on recombinant proteins rather than on reagents that must be produced in high containment laboratories...
  46. Gene Discovery and Heparan Sulfate Biogenesis
    Jeffrey D Esko; Fiscal Year: 2010
    ..Most of the enzymes involved in heparan sulfate biogenesis have been identified, cloned, expressed as recombinant proteins, studied biochemically, and mutated in cells or model organisms...
  47. Preclinical development of recombinant antigen diagnostics for Lassa fever
    Robert F Garry; Fiscal Year: 2010
    ..team has successfully produced prototype LASV enzyme-linked immunosorbent assays (ELISA) that are based on recombinant proteins rather than on reagents that must be produced in high containment laboratories...
  48. IDENTIFICATION OF TARGET ANTIGENS IN MULTIPLE SCHLEROSIS
    BRIAN APATOFF; Fiscal Year: 1993
    ..first is the ability to construct large, high efficiency cDNA libraries from MS brain and express them as recombinant proteins in phage cloning systems...
  49. Protein Biomarkers for Invasive Aspergillosis Diagnostics
    MARTA L FELDMESSER; Fiscal Year: 2012
    ..b>Recombinant proteins then will be used to create monoclonal antibodies that can be used for mass spectrometry-based assay ..
  50. Protein Biomarkers for Invasive Aspergillosis Diagnostics
    MARTA L FELDMESSER; Fiscal Year: 2010
    ..b>Recombinant proteins then will be used to create monoclonal antibodies that can be used for mass spectrometry-based assay ..
  51. Development of a Subunit Vaccine Against Q Fever
    James Samuel; Fiscal Year: 2009
    ..LPS lipid A and core or N-linked glycoprotein, and combine this with protective T cellstimulating recombinant proteins in Recombinant Attenuated Salmonella Vaccines (RASV)...
  52. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 2002
    ..such as lipoproteins and viruses are promising targetable transport systems for low molecular weight drugs, recombinant proteins, and genes...
  53. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 2000
    ..such as lipoproteins and viruses are promising targetable transport systems for low molecular weight drugs, recombinant proteins, and genes...
  54. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 2001
    ..such as lipoproteins and viruses are promising targetable transport systems for low molecular weight drugs, recombinant proteins, and genes...
  55. ARTIFICIAL POLYMERIC LIPOPROTEINS AS DRUG CARRIERS
    GLEN KWON; Fiscal Year: 1999
    ..such as lipoproteins and viruses are promising targetable transport systems for low molecular weight drugs, recombinant proteins, and genes...
  56. Peptide-Based Serological Test for Cysticercosis
    VICTOR KOVALENKO; Fiscal Year: 2007
    ..The tests will utilize standardized antigenic material such as synthetic peptides, recombinant proteins and combinations thereof selected from antigens identified recently in diagnostic bands of Western blots (..
  57. Peptide-Based Serological Test for Cysticercosis
    VICTOR KOVALENKO; Fiscal Year: 2006
    ..The tests will utilize standardized antigenic material such as synthetic peptides, recombinant proteins and combinations thereof selected from antigens identified recently in diagnostic bands of Western blots (..
  58. Nanotube and nanogold to gear phi29 DNA packaging motor
    Peixuan Guo; Fiscal Year: 2007
    ..An imitative motor has been successfully constructed using purified recombinant proteins and artificially synthesized RNA. It can be turned on and off at will...
  59. Nanotube and nanogold to gear phi29 DNA packaging motor
    Peixuan Guo; Fiscal Year: 2004
    ..An imitative motor has been successfully constructed using purified recombinant proteins and artificially synthesized RNA. It can be turned on and off at will...
  60. Nanotube and nanogold to gear phi29 DNA packaging motor
    Peixuan Guo; Fiscal Year: 2005
    ..An imitative motor has been successfully constructed using purified recombinant proteins and artificially synthesized RNA. It can be turned on and off at will...
  61. Nanotube and nanogold to gear phi29 DNA packaging motor
    Peixuan Guo; Fiscal Year: 2006
    ..An imitative motor has been successfully constructed using purified recombinant proteins and artificially synthesized RNA. It can be turned on and off at will...
  62. A new technology for preclinical development of functional bispecific antibodies
    Lee A Henderson; Fiscal Year: 2010
    ..trials, the road to a healthier future will require new methods for producing safer and less expensive recombinant proteins. In particular, next generation therapeutics derived from monoclonal antibodies (e.g...
  63. Recombinant Subunit Vaccine for Tick-Borne Encephalitis
    Beth Ann Coller; Fiscal Year: 2010
    ..The recombinant proteins showed very potent immunogenicity in mice when used with modern adjuvants...
  64. MOLECULAR TARGETS OF CMI IN TYPE I DIABETES
    John Hutton; Fiscal Year: 2000
    ..of cDNA libraries for screening in T-cell proliferation assays, and expression and purification of recombinant proteins. There are 5 specific aims...
  65. Novel Pattern Specific Isotopic Labeling of Aromatic Amino Acids
    Robert McFeeters; Fiscal Year: 2010
    ..Thirdly, the incorporation of pattern specific aromatic labels into a range of recombinant proteins will be characterized...
  66. MOLECULAR TARGETS OF CMI IN TYPE I DIABETES
    John Hutton; Fiscal Year: 1999
    ..of cDNA libraries for screening in T-cell proliferation assays, and expression and purification of recombinant proteins. There are 5 specific aims...
  67. Recombinant Subunit Vaccine for Tick-Borne Encephalitis
    Beth Ann Coller; Fiscal Year: 2009
    ..The recombinant proteins showed very potent immunogenicity in mice when used with modern adjuvants...
  68. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2000
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  69. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2003
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  70. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2002
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  71. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2002
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  72. La Jolla Interdisciplinary Neuroscience Center Cores - Pro Core BU
    Stuart Lipton; Fiscal Year: 2009
    ..The Facility also performs the more routine mass analysis of intact recombinant proteins and synthetic peptides and glycopeptides, protein identification from gel slices/spots using peptide mass ..
  73. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2001
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  74. FUNCTION OF THE KINETOPLAST IN THE HEMOFLAGELLATES
    Larry Simpson; Fiscal Year: 2004
    ..The genes will be cloned and expressed both in E. coli and as tagged proteins in L. tarentolae, and the recombinant proteins used to generate antibodies...
  75. EXPERIMENTAL AUTOIMMUNE GRAVES' DISEASE
    Bellur Prabhakar; Fiscal Year: 2001
    ..Subsequent to cloning of human TSHR, several laboratories, including our own, have used human recombinant proteins to induce the disease in mice...
  76. EXPERIMENTAL AUTOIMMUNE GRAVES' DISEASE
    Bellur Prabhakar; Fiscal Year: 2003
    ..Subsequent to cloning of human TSHR, several laboratories, including our own, have used human recombinant proteins to induce the disease in mice...
  77. EXPERIMENTAL AUTOIMMUNE GRAVES' DISEASE
    Bellur Prabhakar; Fiscal Year: 2002
    ..Subsequent to cloning of human TSHR, several laboratories, including our own, have used human recombinant proteins to induce the disease in mice...
  78. Application of SEREX antigen in multiple myeloma
    SEAH LIM; Fiscal Year: 2006
    ..We have proceeded to clone and produce recombinant proteins of Sp17, SPAN-Xb and SEMG1 and used these proteins to generate antigen-specific murine MoAbs...
  79. Application of SEREX antigen in multiple myeloma
    SEAH LIM; Fiscal Year: 2006
    ..We have proceeded to clone and produce recombinant proteins of Sp17, SPAN-Xb and SEMG1 and used these proteins to generate antigen-specific murine MoAbs...
  80. Application of SEREX antigen in multiple myeloma
    SEAH LIM; Fiscal Year: 2005
    ..We have proceeded to clone and produce recombinant proteins of Sp17, SPAN-Xb and SEMG1 and used these proteins to generate antigen-specific murine MoAbs...
  81. Application of SEREX antigen in multiple myeloma
    SEAH LIM; Fiscal Year: 2007
    ..We have proceeded to clone and produce recombinant proteins of Sp17, SPAN-Xb and SEMG1 and used these proteins to generate antigen-specific murine MoAbs...
  82. EXPERIMENTAL AUTOIMMUNE GRAVES' DISEASE
    Bellur Prabhakar; Fiscal Year: 2000
    ..Subsequent to cloning of human TSHR, several laboratories, including our own, have used human recombinant proteins to induce the disease in mice...